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SIONS: Our model provides evidence than an effective
AIDS intervention in a high-risk population of out-of-
treatment substance abusers can avert significant num-
bers of new HIV infections, which may offset initial
costs.
PID13
ECONOMIC EVALUATION OF ROTAVIRUS 
VACCINATION FOR THE NETHERLANDS
Welte R, Jager J, van Duynhoven Y, de Wit M
National Institute of Public Health and the Environment, 
Bilthoven, Netherlands
OBJECTIVES: To estimate the cost-effectiveness of a na-
tional rotavirus (RV) vaccination program for the Neth-
erlands, from a societal perspective. METHODS: Three
RV-vaccine doses are administered to infants as part of
the routine schedule of childhood immunizations. Based
on clinical trials we assume a vaccine protection duration
of 4 years and a vaccine effectiveness of 55% against
mild RV-diarrhea, 65% against moderate RV-diarrhea
(outpatient treatment), and 80% against severe RV-diar-
rhea (inpatient treatment). Resource consumption caused
by RV-diarrhea is derived from recent national studies
and the findings of expert panels and valued according to
the Dutch costing guidelines. Direct medical (e.g., for
vaccine administration or RV-tests) and non-medical
costs (e.g., for transportation or extra diapers) are con-
sidered. Indirect costs include the productivity loss of
paid (friction cost method) and unpaid work (substitu-
tion approach) caused by parents caring for their sick
child. Costs are presented in 1998 EUR and both future
costs and effects are discounted at 4%. A decision analy-
sis model is employed to calculate the health outcomes
and costs of the vaccination program. RESULTS: RV-
vaccination would avoid 34,300 cases of gastroenteritis
and 2,300 hospitalizations per year. The break-even dose
price of the vaccine is EUR 4 or EUR 9, depending on the
exclusion or inclusion of the productivity loss of unpaid
work. However, at a dose price of the 1999 withdrawn
RV-vaccine (EUR 30) the program would yield costs of
EUR 15,000 (paid work only) or EUR 12,100 (paid and
unpaid work) per avoided hospitalization. These results
are sensitive to the incidence of RV-gastroenteritis, the
vaccine effectiveness, the length of hospitalization, and
the productivity loss caused by RV-gastroenteritis while
variations in outpatient care and direct non-medical costs
have limited influence. CONCLUSIONS: Depending on
its price the RV-vaccine might be a promising candidate
for the Dutch national immunization program.
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PREDICTORS OF THE MENTAL (MHS) AND 
PHYSICAL HEALTH SUMMARY (PHS) SCORES 
OF THE MOS-HIV IN A SAMPLE OF
HIV-INFECTED PATIENTS
Griffis DL, Delate T, Coons SJ
The University of Arizona, Tucson, AZ, USA
OBJECTIVE: Studies evaluating predictors of heath-
related quality-of-life (HRQOL) in patients infected with
HIV have primarily been limited to clinical, sociodemo-
graphic, and psychological factors. Little is known about
the relationship between HRQOL and behaviors such as
medication adherence or complementary and alternative
medicine (CAM) use. The purpose of this study was to
determine the clinical, sociodemographic, and behavioral
predictors of HRQOL. METHODS: A sample of 242
HIV-infected patients was recruited. Data were collected
using a self-administered instrument containing the Med-
ical Outcomes Study (MOS)-HIV Health Survey and
items relating to CAM use, medication adherence, and
sociodemographic characteristics. Clinical information
was abstracted from medical records. Independent asso-
ciations of the Mental (MHS) and Physical Health Sum-
mary (PHS) scores with CD4 cell counts, HIV-1 viral
loads, CAM use, self-reported medication adherence, an-
tiretroviral use, and sociodemographic characteristics
were assessed. Linear regression models were created for
each score. Variables independently associated (p  0.05)
with a score were entered into that model. RESULTS: The
mean MHS and PHS scores were 46.6 and 42.8, respectively.
Education, income, CAM use, and self-reported adher-
ence to HIV medication regimens were independently as-
sociated (p  0.03) with MHS scores. PHS scores were
independently associated (p  0.003) with age, income,
HIV-1 viral load, CD4 count, and CAM use. In the mul-
tivariate analyses, income and self-reported adherence
were found to be significant (p  0.005) predictors of the
MHS scores (Adj. R2  0.197); age, income, CD4
counts, and CAM use were found to be significant (p 
0.03) predictors of PHS scores (Adj. R2  0.182). CON-
CLUSIONS: Our research suggests that, along with clini-
cal and sociodemographic characteristics, self-reported
behaviors are important predictors of HRQOL among
HIV-infected patients.
PID15
MANAGING AIDS IN THE ERA OF 
ANTIRETROVIRAL THERAPY: CHANGES IN THE 
RATE AND COST OF HOSPITALIZATIONS
O’Brien JA, Pierce D, Patrick AR, Caro JJ
Caro Research Institute, Concord, MA, USA
BACKGROUND: Clinical trials have shown that highly
active antiretroviral therapy (HAART) alters the natural
progression of HIV. This study was undertaken to deter-
mine if, apart from the beneficial clinical impact, there
has been a change in the cost of AIDS-related care.
METHODS: Data from the Massachusetts (MA) Depart-
ment of Public Health and hospital discharge databases
for 1995–1998 were used to examine changes in hospital
admission and discharge patterns, and hospital costs for
adults with AIDS across the four years. Analyses involved
log transformation to address highly skewed distribu-
tions, ANOVA to compare continuous variables and Chi-
Square to compare the proportions. Hospital costs in-
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clude all accommodations and ancillaries. Cost estimates,
adjusted for medical inflation and cost-to-charge ratios,
are reported in 1998 US$. RESULTS: From 1995 to
1998, the rate of hospital admissions for MA residents
with AIDS declined substantially. In 1995, 86% of the
3,162 AIDS patients were admitted at least once during
the year compared to 31% of the 5,636 patients in 1998.
The mean number of annual admissions per patient
dropped from 2 to 1.76 and the inpatient case fatality
rate fell from 6.7% to 4.6%. The mean LOS per AIDS
admission fell by 1.3 days; a greater decline than the 0.4
day average observed in MA over the same period. The
mean hospital stay cost decreased from $8,070 to
$7,538. These changes accounted for a $2,900 drop in
the mean annual hospitalization cost per AIDS patient
during that time. Discharge to sub-acute inpatient and
home health services fell by 8.6% in this period. All
changes reported are statistically significant (p  0.05).
CONCLUSIONS: The change in LOS is not the result of
post-discharge resource use shifting. The decrease in re-
source use and costs observed after the introduction of
HAART are consistent with an economically beneficial
impact of these agents.
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COST BURDEN OF VARICELLA-ZOSTER VIRUS 
INFECTION IN A MANAGED CARE SETTING
Schaffer M1, Liu M1, Scott W2, Mansukani S1
1Health Partners, Inc, Philadelphia, PA, USA; 2Hospital of the 
University of Pennsylvania, Philadelphia, PA, USA
Although information exists in the form of projected
costs, limited data are available on the overall cost of ill-
ness resulting from varicella-zoster virus (VZV) infection.
VZV is usually a benign childhood illness, but reactiva-
tion of latent VZV can lead to serious complications.
OBJECTIVE: To assess via medical claims the costs asso-
ciated with VZV infection and its resultant complications
from the payers’ perspective. METHODS: We conducted
a retrospective database analysis of 73,869 managed care
members continuously enrolled throughout calendar year
1999. Records of members with a diagnosis code of ei-
ther primary varicella (ICD9-052) or herpes zoster (ICD-
053) were selected. Data was extracted and cost information
was tallied for all medical claims including inpatient hos-
pitalizations, primary care visits, specialist visits, emer-
gency department visits, and specialty procedures. Cost
data are reported in 1999 US dollars. RESULTS: In 1999,
a total of 119 patients were diagnosed with varicella
(52%) and herpes zoster (48%). The mean cost to the
payer was $496.77/patient. The average amount paid out
for members with varicella was $181.87. The average
cost per member with herpes zoster was $786.27. Sixty-
two (52%) VZV afflicted members were diagnosed with
varicella while 57 were diagnosed with herpes zoster. The
amount paid for members over age 19 (n  56) was
$640.30/patient. Of these patients, 14% were classified
with varicella infection, whereas 86% were classified as
having zoster. For members aged 19 (n  63), the mean
amount paid was $369.18/patient. In this group, 78%
were diagnosed with varicella infection, whereas 22%
were diagnosed with zoster. CONCLUSION: The above
costs document for the first time the true cost of VZV in-
fection from the payers’ perspective. Further efforts to
expand vaccination programs should take these costs into
consideration.
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ECONOMIC EVALUATION OF OSELTAMIVIR 
FOR INFLUENZA PATIENTS IN JAPAN
Kobayashi M
Crecon Research and Consulting Inc, Tokyo, Japan
OBJECTIVES: The aim of this analysis is to estimate the
economic impacts of oseltamivir treatment for influenza
in Japan. METHODS: A decision tree with endpoints of
occurrences of pneumonia was constructed to compare
two treatment strategies, oseltamivir treatment and con-
ventional treatment, for otherwise healthy adult (over 16)
patients with influenza like illness in Japan. Drug con-
sumption data (e.g., acetaminophen, antibiotics, and pal-
liative drugs for influenza like illness related symptoms)
were collected prospectively as well as work absenteeism
data as part of the Japanese placebo-controlled double-
blind multicenter study by oseltamivir that included 316
patients. Parameters used in the decision tree were mainly
derived from this study and combined with published
data. Sensitivity analyses were also performed to examine
the robustness of the results. RESULTS: Expected total
medical cost per patient was 14,100 yen and 14,412 yen
for oseltamivir treatment and conventional treatment, re-
spectively. Expected cost including production loss was
56,654 yen and 63,485 yen, for oseltamivir treatment
and conventional treatment, respectively. Based on the
results of basic analyses, the savings that could be ex-
pected in Japanese nationwide health care costs with
widespread use of oseltamivir ranged from 1.1 billion yen to
3.4 billion yen. CONCLUSION: This study suggested that
oseltamivir treatment for patients with flu-like symptoms
can be attractive from the societal perspective in Japan.
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METHICILLIN-RESISTANT STAPHYLOCOCCUS 
SPECIES TREATMENT PATTERNS IN CANADA
Becker D, Rosner AJ
Innovus Research Inc, Burlington, ON, Canada
Antibiotic resistance is of growing importance to the Ca-
nadian health care system due to the morbidity, mortal-
ity, and financial costs of certain pathogens for which
there are limited therapeutic options. Among the resistant
organisms, the incidence of methicillin-resistant Staphy-
lococcus species (MRSS) is rising and is posing an in-
creasing burden to health care systems. OBJECTIVE: To
characterize MRSS treatment patterns in patients with
